Clinical Trial

NW-301 TCR-T in Patients With Advanced Solid Tumor

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor
Trial Details
NCT Number NCT06956261
Lead Sponsor Peking University
Conditions Tumor, Solid
Enrollment 44 participants
Start Date 2025-05-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-04